经皮冠状动脉介入治疗术后支架内再狭窄因素的探讨
Discussion on the Factors of In-Stent Restenosis after Percutaneous Coronary Intervention
摘要: 支架内再狭窄是冠心病介入治疗中面临的重大医学题，也是研究的热点，其主要发生机制尚不清楚，可能与平滑肌过度增生，血管壁的重塑，炎症反应等有关，且其影响因素众多。现就支架内再狭窄的影响因素予以综述。
Abstract: In-stent restenosis is a major medical problem in the interventional treatment of coronary heart disease, and is also a research hotspot. Its main mechanism is still unclear, which may be related to smooth muscle hyperplasia, vascular wall remodeling, inflammatory response, etc., and its influencing factors are numerous. This article reviews the influencing factors of in-stent restenosis.
文章引用：马博博, 王晨霞. 经皮冠状动脉介入治疗术后支架内再狭窄因素的探讨[J]. 临床医学进展, 2021, 11(8): 3638-3643. https://doi.org/10.12677/ACM.2021.118533

参考文献

[1] 《心肺血管病杂志》编辑部. 中国心血管健康与疾病报告2019 [J]. 心肺血管病杂志, 2020, 39(9): 1145-1156.
[2] 北京高血压防治协会, 北京糖尿病防治协会, 北京慢性病防治与健康教育研究会, 高血压联盟(中国), 中国老年保健协会养老与健康专业委员会, 国家老年疾病临床医学研究中心中国老年心血管, 等. 基层心血管病综合管理实践指南2020 [J]. 中国医学前沿杂志(电子版), 2020, 12(8): 1, 1-73.
[3] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员. 经皮冠状动脉介入治疗指南(2009) [J]. 中华心血管病杂志, 2009, 37(1): 4-25.
[4] Mehran, R., Dangas, G., Abizaid, A.S., Mintz, G.S., Lansky, A.J., Satler, L.F., et al. (1999) Angiographic Patterns of In-Stent Restenosis: Classification and Implications for Long-Term Outcome. Circulation, 100, 1872-1878. [Google Scholar] [CrossRef] 
[5] Park, H.J., Seo, S.M., Shin, W.S., Kim, H.-Y., Choi, Y.S., Koh, Y.S., et al. (2011) Soluble Receptor for Advanced Glycation End Products Is Associated with In-Stent Restenosis in Patients with Type 2 Diabetes with Drug-Eluting Coronary Stents. Coronary Artery Disease, 22, 12-17. [Google Scholar] [CrossRef] 
[6] Alsever, R.N., Thomas, W.M., Nevin-Woods, C., et al. (2009) Reduced Hospitalizations for Acute Myocardial Infarction after Implementation of a Smoke-Free Ordinance-City of Pueblo, Colorado, 2002-2006. JAMA, 301, 480-483. [Google Scholar] [CrossRef] 
[7] Yonetsu, T., Kato, K., Kim, S.J., Xing, L., Jia, H., McNulty, I., et al. (2012) Predictors for Neoatherosclerosis: A Retrospective Observational Study from the Optical Coherence Tomography Registry. Circulation: Cardiovascular Imaging, 5, 660-666. [Google Scholar] [CrossRef] 
[8] Li, Y., Ming, T.X., Yuan, L., Chen, B., Xu, Z.R., Guo, Q.H., et al. (2016) Prevalence of Dyslipidemia and Its Control in Type 2 Diabetes: A Multicenter Study in Endocrinology Clinics of China. Journal of Clinical Lipidology, 10, 150-160. [Google Scholar] [CrossRef] [PubMed]
[9] Li, S., Luo, C. and Chen, H. (2021) Risk Factors of In-Stent Restenosis in Patients with Diabetes Mellitus after Percutaneous Coronary Intervention. Medicine, 100, e25484. [Google Scholar] [CrossRef] [PubMed]
[10] Apelberg, B.J., Onicescu, G., Avila-Tang, E. and Samet, J.M. (2010) Estimating the Risks and Benefits of Nicotine Replacement Therapy for Smoking Cessation in the United States. American Journal of Public Health, 100, 341-348. [Google Scholar] [CrossRef] [PubMed]
[11] Hardoon, S.L., Whincup, P.H., Petersen, I., Capewell, S. and Morris, R.W. (2011) Trends in Longer-Term Survival Following an Acutemyocardial Infarction and Prescribing of Evidenced-Based Me Dications in Primary Care in the UK from 1991: A Longitudinal Population-Based Study. Journal of Epidemiology & Community Health, 65, 770-774. [Google Scholar] [CrossRef] [PubMed]
[12] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 中华医学会心血管病学分会预防学组,中华医学会心血管病学分会康复学组, 中华医学会《中华全科医师杂志》编辑委员会, 心血管系统疾病基层诊疗指南编写专家组. 冠心病心脏康复基层指南(2020年) [J].中华全科医师杂志, 2021, 20(2): 150-165.
[13] Akhabue, E., Thiboutot, J., Cheng, J.W., Vittorio, T.J., Christodoulidis, G., Grady, KM., et al. (2014) New and Emerging Risk Factors for Coronary Heart Disease. The American Journal of the Medical Sciences, 347, 151-158.
[14] 凌政, 吕海权, 陆敏, 翚崇柳, 雷敏, 谭子烈, 等. H型高血压与冠心病冠脉病变严重程度的关系研究[J]. 右江医学, 2014, 42(6): 637-640.
[15] 张明玺, 罗俊. H型高血压的病因及发病机制[J]. 心血管病学进展, 2012, 33(2): 253-256．
[16] Yayla, K.G., Canpolat, U., Yayla, C., Akboğa, M.K., Akyel, A., Akdi, A., et al. (2017) A Novel Marker of Impaired Aortic Elasticity in Never Treated Hypertensive Patients: Monocyte/High-Density Lipoprotein Cholesterol Ratio. Acta Cardiologica Sinica, 33, 41-49.
[17] Ucar, F.M. (2016) A Potential Marker of Bare Metal Stent Restenosis: Monocyte Count-to-HDL Cholesterol Ratio. BMC Cardiovasc Disord, 16, Article No. 186. [Google Scholar] [CrossRef] [PubMed]
[18] Tok, D., Turak, O., Yayla, C., Ozcan, F., Tok, D. and Çağlı, K. (2016) Monocyte to HDL Ratio in Prediction of BMS Restenosis in Subjects with Stable and Unstable Angina Pectoris. Biomarkers in Medicine, 10, 853-860. [Google Scholar] [CrossRef] [PubMed]
[19] Maheronnaghsh, M., Niktab, I., Enayati, S., Amoli, M.M., Hosseini, S.K. and Tavakkoly-Bazzaz J. (2021) Differentially Expressed miR-152, a Potential Biomarker for In-Stent Restenosis (ISR) in Peripheral Blood Mononuclear Cells (PBMCs) of Coronary Artery Disease (CAD) Patients. Nutrition, Metabolism & Cardiovascular Diseases, 31, 1137-1147. [Google Scholar] [CrossRef] [PubMed]
[20] Chen, L.Y., Wu, F.F., Yuan, S.J. and Feng, B. (2016) Identification and Characteristic of Three Members of the C1q/TNF-Related Proteins (CTRPs) Superfamily in Eudontomyzonmorii. Fish & Shellfish Immunology, 59, 233-240. [Google Scholar] [CrossRef] [PubMed]
[21] Yi, W., Sun, Y., Yuan, Y., Lau, W.B., Zheng, Q., Wang, X., et al. (2012) C1q/Tumor Necrosis Factor-Related Protein-3, a Newly Identified Adipokine, Is a Novel Antiapoptotic, Proangiogenic, and Cardioprotective Molecule in the Ischemic Mouse Heart. Circulation, 125, 3159-3169. [Google Scholar] [CrossRef] [PubMed]
[22] 杨铠榕. CTRP3与冠脉药物洗脱支架置入术后支架内再狭窄的相关性研究[D]: [硕士学位论文]. 延安: 延安大学, 2018.
[23] Alessandro, L., Secco, G.G., Rognoni, A., Rossi, L., Lazzero, M, Nardi, F., et al. (2012) Plasma Fibrinogen Levels and Restenosis after Primary Percutaneous Coronary Intervention. Journal of Thrombosis and Thrombolysis, 33, 308-317. [Google Scholar] [CrossRef] [PubMed]
[24] Roche, M., Rondeau, P., Singh, N.R., Tarnus, E. and Bourdon, E. (2008) The Antioxidant Properties of Serum Albumin. FEBS Letters, 582, 1783-1787. [Google Scholar] [CrossRef] [PubMed]
[25] Karahan, O., Acet, H., Ertaş, F., Tezcan, O., Çalişkan, A., Demir, M., et al. (2016) The Relationship between Fibrinogen to Albumin Ratio and Severity of Coronary Artery Disease in Patients with STEMI. The American Journal of Emergency Medicine, 34, 1037-1042. [Google Scholar] [CrossRef] [PubMed]
[26] Albertal, M., Abizaid, A., Muñoz, J.S., Mintz, G.S., Abizaid, A.S., Feres, F., et al. (2005) A Novel Mechanism Explaining Early Lumen Loss Following Balloon Angioplasty for the Treatment of In-Stent Restenosis. American Journal of Cardiology, 95, 751-754. [Google Scholar] [CrossRef] [PubMed]
[27] 张辉, 许官学. 心肌桥与冠状动脉内支架植入术后再狭窄的相关性研究[J]. 大家健康(学术版), 2016, 10(8): 10-11.
[28] Hecht, H.S., Polena, S., Jelnin, V., Jimenez, M., Bhatti, T., Parikh, M., et al. (2009) Stent Gap by 64-Detector Computed Tomographic Angiography Relationship to In-Stent Restenosis, Fracture, and Overlap Failure. Journal of the American College of Cardiology, 54, 1949-1959. [Google Scholar] [CrossRef] [PubMed]
[29] Sahara, M., Kirigaya, H., Oikawa, Y., Yajima, J., Ogasawara, K., Satoh, H., Nagashima, K., Hara, H., Nakatsu, Y. and Aizawa, T. (2003) Arterial Remodeling Patterns before Intervention Predict Diffuse In-Stent Restenosis. Journal of the American College of Cardiology, 42, 1731-1738.
[30] Pocock, S., Lansky, A., Mehran, R., Popma, J.J., Fahy, M.P., Na, Y., et al. (2008) Angiographic Surrogate End Points in Drug-Eluting Stent Trials: A Systematic Evaluation Based on Individual Patient Data from 11 Randomized, Controlled Trials. Journal of the American College of Cardiology, 51, 23-32. [Google Scholar] [CrossRef] [PubMed]
[31] 杨铠榕, 周静, 刘卫生. 冠状动脉粥样硬化性心脏病药物支架植入术后支架内再狭窄影响因素分析[J]. 岭南心血管病杂志, 2017, 23(4): 488-491.
[32] Omer, G., Tezcan, A.E., Tunckol, H., Emül, H.M., et al. (2005) High Serum Leptin Levels in Depressive Disorders with Atypical Features. Psychiatry and Clinical Neurosciences, 59, 736-738. [Google Scholar] [CrossRef] [PubMed]

为你推荐